secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001099800-23-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire
--------------------------------------------------------------------------------

- Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.
- TAVR sales $948M (+8% YoY, +11% cc); TMTT $42M; Surgical $248M; Critical Care $222M.
- Full-year sales guidance raised to high end of $5.6-6.0B; adj EPS guidance raised to $2.48-2.60.
- Repurchased ~$250M stock in Q1; free cash flow $253M.
- CEO Michael Mussallem retiring next month; Bernard Zovighian to succeed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/0001099800-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/ew-20230426.htm
  HTML page:      https://secwatch.observer/filing/0001099800-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer